Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia-feasibility and safety study

Journal of Clinical Immunology

Volumn 28, Issue 4, 2008, Pages 390-397

  Huang, Xiao Jun ^a   Wang, Yu ^a   Liu, Dai Hong ^a   Xu, Lan Ping ^a   Chen, Huan ^a   Chen, Yu Hong ^a   Han, Wei ^a   Shi, Hong Xia ^a   Liu, Kai Yan ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Advanced leukemia; Donor lymphocytes infusion; Granulocyte colony stimulating factor; Hematopoietic stem cell transplantation

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY CD3; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEMUSTINE; TACROLIMUS; THALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER RELAPSE; CELL COUNT; CHILD; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DONOR LYMPHOCYTE INFUSION; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA TYPING; HUMAN; MALE; MONONUCLEAR CELL; MONOTHERAPY; MORTALITY; MULTIPLE CYCLE TREATMENT; MYELOPROLIFERATIVE DISORDER; OVERALL SURVIVAL; PANCYTOPENIA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RADIATION DOSE; SHORT COURSE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR REGRESSION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; FEASIBILITY STUDIES; FEMALE; GRAFT VS HOST DISEASE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA; LYMPHOCYTE TRANSFUSION; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; TISSUE DONORS;

EID: 46749137540     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-008-9193-4     Document Type: Article

References (27)

1. Huang XJ, Guo NL, Ren HY. An improved anti-leukemic effect achieved with donor progenitor cell infusion for relapse patients after allogeneic bone marrow transplantation. Chin Med J. 2003;116:736-41.
2. Huang XJ, Liu DH, Xu LP. Prophylactic infusion of donor granulocyte colony stimulating factor mobilized peripheral blood progenitor cells after allogeneic hematological stem cell transplantation in patients with high-risk leukemia. Leukemia 2006;20:365-8.
3. De Lima M, Bonamino M, Vasconcelos Z. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease. Bone Marrow Transplant. 2001;27:73-8.
4. Huang XJ, Chang YJ, Zhao XY. In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Haematologica 2004;89:1517-24.
5. Chen SH, Li X, Huang XJ. Effect of recombinant granulocyte colony-stimulating factor on T-lymphocyte function and the mechanism of this effect. Int J Hematol. 2004;79:178-84.
6. Mengarelli A, Iori A, Guglielmi C. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Haematologica 2002;87:52-8.
7. Zhou J, Guo NL, Zheng H. Comparison of two conditioning regimens in allogeneic bone marrow transplantation. Chin J Hematol. 1996;17:64-6.
8. Devergie A. Graft vs. host disease. In: Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T, editors. Haematopoietic stem cell transplantation: the EBMT handbook. Rev ed. Paris, France: European School of Hematology; 2004. p. 168-9.
9. Durnam DM, Anders KR, Fisher L. Analysis of the origin of marrow cells in bone marrow transplant recipients using a Y-chromosome-specific in situ hybridization assay. Blood 1989;74:2220-6.
10. Anslinger K, Rolf B, Keil W. Evaluation and application of the AmpF/STR profiler plus PCR amplification kit in a Bavarian population sample. Int J Legal Med. 2001;114:278-80.
11. Edenfield WJ, Gore SD. Stage-specific application of allogeneic and autologous marrow transplantation in the management of acute myeloid leukemia. Semin Oncol. 1999;26:21-34.
12. Robak T, Wrzesien-Kus A. The search for optimal treatment in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma. 2002;43:281-91.
13. Frassoni F. Stem cell transplantation in adults: acute leukemia. In: Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T, editors. Haematopoietic stem cell transplantation: the EBMT handbook. Rev ed. Paris, France: European School of Hematology; 2004. p. 239-54.
14. Biggs JC, Horowitz MM, Gale RP. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 1992;80:1090-3.
15. Ringden O, Horowitz M, Gale RP. Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA 1993;270:57-60.
16. Singhal S, Powles R, Henslee-Downey PJ. Allogeneic transplantation from HLA-matched sibling or partially HLA-mismatched related donors for primary refractory acute leukemia. Bone Marrow Transplant. 2002;29:291-5.
17. Alessandrino EP, Bernasconi P, Caldera D. Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999;23:607-12.
18. Slavin S, Naparstek E, Nagler A. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996;87:2195-204.
19. Levine JE, Braun T, Penza SL. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol. 2002;20:405-12.
20. Kolb HJ, Schattenberg A, Goldman JM. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working party Chronic Leukemia. Blood 1995;86:2041-50.
21. Huang XJ, Liu DH, Liu KY. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007;92:414-7.
22. Sohn SK, Jung JT, Kim DH, Lee NY, Seo KW, Chae YS, et al. Prophylactic growth factor-mobilized donor lymphocyte infusion using cells reserved at the time of transplantation after allogeneic peripheral blood stem cell transplantation in patients with high-risk hematologic malignancies. Cancer 2002;94:18-24.
23. Huang XJ, Chang YJ, Zhao XY. Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. Transplant Immunol. 2007;17:193-7.
24. Pawson R, Potter MN, Theocharous P. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG+/- Ida) and second allogeneic stem cell transplant. Br J Haematol. 2001;115:622-9.
25. Michallet M, Thomas X, Vernant JP. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplant. 2000;26:1157-63.
26. Clift RA, Buckner CD, Appelbaum FR. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol. 1992;10:1723-9.
27. Schmid C, Schleuning M, Schwerdtfeger R. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006;108:1092-9.